Gilead Sciences: FDA Fully Approves Trodelvy for Metastatic TNBC

Gilead Sciences is Granted FDA Approval for Trodelvy®
Gilead Sciences (GILD), a company that has been granted more approvals than many are aware of except for the short analysts and their followers, today announced that the U.S. FDA has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.